SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
August 01, 2023 09:00 ET
|
SciSparc Ltd
TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia and...
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
July 11, 2023 08:15 ET
|
Purple Biotech Ltd.
Purple’s innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3rd line PDAC patientsRandomized Phase 2 study is enrolling as expected with initial Phase 2...
Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation
June 29, 2023 08:05 ET
|
Semper Paratus Acquisition Corporation
Tevogen Bio Inc. (“Tevogen Bio”) is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and...
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
June 28, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal...
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
June 26, 2023 17:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
June 23, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, June 23, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the “Company”) announced today that it has received confirmation from The Nasdaq Stock...
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
April 24, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has been shown in multiple animal studies across a spectrum of cancers ...
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors
April 24, 2023 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its...
Neuronascent Announces the Expansion of its Board of Directors
April 12, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer...
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 10, 2023 08:30 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 10, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common...